On Our Radar: Deals we are paying attention to for their impact on industry. Biotech firm Cullgen’s April 10 announcement that it had received a $16 million Series A financing aimed at advancing treatment of cancer and inflammatory and autoimmune diseases in a fresh way is another sign of the growing competition in this emerging […]

THIS ARTICLE IS EXCLUSIVE FOR KARMA MEMBERS

If you are an existing Karma member, please login using the form below.

If you are a guest, you can access this article - plus much more - with our 7-day FREE trial. Click here to register. No credit card required.